Menu
Search
|

Menu

Close
X

Kala Pharmaceuticals Inc KALA.OQ (NASDAQ Stock Exchange Global Select Market)

12.58 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 12.58
Open --
Volume --
3m Avg Volume 50,296
Today’s High --
Today’s Low --
52 Week High 26.74
52 Week Low 11.81
Shares Outstanding (mil) 24.23
Market Capitalization (mil) 547.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.460
FY17
-3.061
FY16
-1.425
FY15
-0.412
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
88.50
16.72
LT Debt to Equity (MRQ)
vs sector
68.25
12.39
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Mark Iwicki
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: $500,588.00
Bonus: $387,450.00
Mary Reumuth
Chief Financial Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Todd Bazemore
Chief Operating Officer, Since 2017
Salary: $46,731.00
Bonus: $190,000.00
Hongming Chen
Chief Scientific Officer, Since 2014
Salary: $322,086.00
Bonus: $129,944.00
Eric Trachtenberg
General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Beaver St Ste 201
WALTHAM   MA   02453-8425

Phone: +1781.9965252
Site: kalarx.com/

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.

SPONSORED STORIES